Share Price and Basic Stock Data
Last Updated: January 20, 2026, 10:16 pm
| PEG Ratio | -1.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Trigyn Technologies Ltd, operating in the IT Consulting and Software sector, reported a current market price of ₹62.2 and a market capitalization of ₹191 Cr. The company’s revenue trajectory illustrates fluctuations over recent quarters. Sales stood at ₹1,273 Cr for the fiscal year ending March 2023, a rise from ₹1,041 Cr in FY 2022. However, the trailing twelve months (TTM) revenue declined to ₹913 Cr, indicating potential challenges in maintaining consistent growth. Quarterly sales peaked at ₹339.78 Cr in December 2022 but exhibited a downward trend in subsequent quarters, falling to ₹306.90 Cr by December 2023. This decline suggests possible market pressures or operational inefficiencies that require scrutiny. The overall sales growth from FY 2022 to FY 2023 reflects a compound annual growth rate (CAGR) of approximately 11.2%, yet the recent quarterly performance poses concerns about sustaining momentum in a competitive landscape.
Profitability and Efficiency Metrics
Trigyn Technologies recorded a net profit of ₹4 Cr for the fiscal year ending March 2023, down from ₹35 Cr in the previous fiscal year, highlighting a notable decrease in profitability. The operating profit margin (OPM) was reported at 5% for FY 2023, a decline from 6% in FY 2022, suggesting that operational efficiencies may be waning. The company’s return on equity (ROE) stood at a low 1.72%, which is considerably below typical industry benchmarks, indicating underperformance in generating returns for shareholders. Furthermore, the interest coverage ratio (ICR) at 12.76x suggests adequate capacity to cover interest expenses, but the overall profitability metrics raise red flags regarding operational effectiveness. The cash conversion cycle (CCC) of 99 days indicates a significant delay in converting investments into cash flows, which could affect liquidity. Overall, while Trigyn maintains some profitability, the downward trends in key metrics necessitate strategic interventions to enhance operational performance.
Balance Sheet Strength and Financial Ratios
As of March 2025, Trigyn Technologies’ balance sheet reflected total assets of ₹903 Cr, with liabilities amounting to ₹903 Cr, indicating a balanced leverage with no long-term debt. Borrowings stood at ₹7 Cr, showcasing a conservative approach to financing. The company has accumulated reserves of ₹731 Cr, providing a cushion against market volatility. The price-to-book value (P/BV) ratio at 0.28x indicates that the stock is trading at a significant discount to its book value, suggesting potential undervaluation. However, the low return on capital employed (ROCE) of 4.17% raises concerns about the effective utilization of capital. The current ratio of 4.82x indicates strong liquidity, while the quick ratio of 4.76x reinforces this position. These ratios suggest that while the company is in a stable financial position, the low returns on equity and capital employed highlight inefficiencies that could hinder growth prospects.
Shareholding Pattern and Investor Confidence
Trigyn Technologies exhibits a stable shareholding pattern, with promoters holding 44.51% of the shares consistently from December 2022 to September 2025. This level of promoter holding reflects a solid commitment to the company, potentially instilling confidence among investors. The public holds 55.35% of the shares, suggesting a diversified shareholder base, yet foreign institutional investors (FIIs) and domestic institutional investors (DIIs) have minimal stakes, at 0.14% and 0.01% respectively. This lack of institutional interest may raise concerns about broader market confidence in the company’s growth trajectory. The number of shareholders stood at 34,157 as of September 2025, indicating a stable retail investor base. However, the declining number of shareholders from 38,413 in December 2022 to 34,157 suggests a potential loss of interest, which could be linked to the company’s recent financial performance and profitability issues.
Outlook, Risks, and Final Insight
Looking ahead, Trigyn Technologies faces a mixed outlook characterized by both opportunities and challenges. The company’s strong liquidity position and substantial reserves provide a foundation for potential investments in growth initiatives. However, the declining sales and profitability metrics present significant risks. Operational inefficiencies and market competition could further pressure margins and net profits. The company’s ability to adapt to changing market conditions and enhance operational efficiencies will be crucial for recovery. Furthermore, the low institutional interest may limit access to capital for expansion. To navigate these challenges, Trigyn must focus on strategic improvements in operational performance and investor relations. Should the company successfully implement efficiency measures and regain market confidence, it could turn around its current trajectory; otherwise, continued financial strain may impede growth and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Visesh Infotecnics Ltd | 125 Cr. | 0.33 | / | 1.11 | 0.00 % | 2.21 % | 2.23 % | 1.00 | |
| Mudunuru Ltd | 62.6 Cr. | 19.8 | 21.0/4.43 | 0.20 | 0.00 % | 27.0 % | 90.7 % | 2.00 | |
| Naapbooks Ltd | 125 Cr. | 116 | 194/99.8 | 19.1 | 36.4 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 41.9 Cr. | 327 | 333/140 | 26.2 | 26.7 | 0.31 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 5.56 Cr. | 1.03 | 1.73/0.91 | 2.47 | 0.00 % | 2.14 % | 2.15 % | 2.00 | |
| Industry Average | 20,262.86 Cr | 536.27 | 81.01 | 123.73 | 0.59% | 14.88% | 20.92% | 6.84 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 323.64 | 339.78 | 324.04 | 322.50 | 316.12 | 306.90 | 334.14 | 241.94 | 207.80 | 206.78 | 239.66 | 224.50 | 241.95 |
| Expenses | 306.53 | 317.16 | 316.07 | 304.80 | 299.96 | 323.41 | 316.78 | 232.47 | 203.44 | 207.41 | 234.15 | 226.82 | 239.76 |
| Operating Profit | 17.11 | 22.62 | 7.97 | 17.70 | 16.16 | -16.51 | 17.36 | 9.47 | 4.36 | -0.63 | 5.51 | -2.32 | 2.19 |
| OPM % | 5.29% | 6.66% | 2.46% | 5.49% | 5.11% | -5.38% | 5.20% | 3.91% | 2.10% | -0.30% | 2.30% | -1.03% | 0.91% |
| Other Income | 1.27 | 2.47 | 2.23 | 3.21 | 3.10 | 2.42 | 3.26 | 4.00 | 3.18 | 4.40 | 3.96 | 4.19 | 4.05 |
| Interest | 0.53 | 0.54 | 0.47 | 0.42 | 0.38 | 0.33 | 0.53 | 0.33 | 0.27 | 0.29 | 1.88 | 0.54 | 0.63 |
| Depreciation | 1.67 | 1.70 | 1.78 | 1.67 | 1.58 | 1.55 | 2.07 | 1.27 | 1.47 | 1.03 | 1.24 | 0.78 | 0.86 |
| Profit before tax | 16.18 | 22.85 | 7.95 | 18.82 | 17.30 | -15.97 | 18.02 | 11.87 | 5.80 | 2.45 | 6.35 | 0.55 | 4.75 |
| Tax % | 33.19% | 32.87% | 67.42% | 35.76% | 37.17% | 37.88% | -5.33% | 35.89% | 93.79% | 49.80% | 59.69% | 940.00% | -10.95% |
| Net Profit | 10.81 | 15.34 | 2.59 | 12.09 | 10.86 | -22.02 | 18.98 | 7.61 | 0.36 | 1.23 | 2.56 | -4.61 | 5.27 |
| EPS in Rs | 3.51 | 4.98 | 0.84 | 3.93 | 3.53 | -7.15 | 6.17 | 2.47 | 0.12 | 0.40 | 0.83 | -1.50 | 1.71 |
Last Updated: December 28, 2025, 6:31 pm
Below is a detailed analysis of the quarterly data for Trigyn Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 241.95 Cr.. The value appears strong and on an upward trend. It has increased from 224.50 Cr. (Jun 2025) to 241.95 Cr., marking an increase of 17.45 Cr..
- For Expenses, as of Sep 2025, the value is 239.76 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 226.82 Cr. (Jun 2025) to 239.76 Cr., marking an increase of 12.94 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.19 Cr.. The value appears strong and on an upward trend. It has increased from -2.32 Cr. (Jun 2025) to 2.19 Cr., marking an increase of 4.51 Cr..
- For OPM %, as of Sep 2025, the value is 0.91%. The value appears strong and on an upward trend. It has increased from -1.03% (Jun 2025) to 0.91%, marking an increase of 1.94%.
- For Other Income, as of Sep 2025, the value is 4.05 Cr.. The value appears to be declining and may need further review. It has decreased from 4.19 Cr. (Jun 2025) to 4.05 Cr., marking a decrease of 0.14 Cr..
- For Interest, as of Sep 2025, the value is 0.63 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.54 Cr. (Jun 2025) to 0.63 Cr., marking an increase of 0.09 Cr..
- For Depreciation, as of Sep 2025, the value is 0.86 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.78 Cr. (Jun 2025) to 0.86 Cr., marking an increase of 0.08 Cr..
- For Profit before tax, as of Sep 2025, the value is 4.75 Cr.. The value appears strong and on an upward trend. It has increased from 0.55 Cr. (Jun 2025) to 4.75 Cr., marking an increase of 4.20 Cr..
- For Tax %, as of Sep 2025, the value is -10.95%. The value appears to be improving (decreasing) as expected. It has decreased from 940.00% (Jun 2025) to -10.95%, marking a decrease of 950.95%.
- For Net Profit, as of Sep 2025, the value is 5.27 Cr.. The value appears strong and on an upward trend. It has increased from -4.61 Cr. (Jun 2025) to 5.27 Cr., marking an increase of 9.88 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.71. The value appears strong and on an upward trend. It has increased from -1.50 (Jun 2025) to 1.71, marking an increase of 3.21.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 451 | 492 | 625 | 679 | 685 | 895 | 911 | 985 | 1,041 | 1,273 | 1,280 | 898 | 913 |
| Expenses | 407 | 456 | 563 | 612 | 623 | 810 | 833 | 893 | 975 | 1,212 | 1,245 | 880 | 908 |
| Operating Profit | 44 | 36 | 62 | 67 | 61 | 85 | 77 | 92 | 65 | 61 | 35 | 18 | 5 |
| OPM % | 10% | 7% | 10% | 10% | 9% | 9% | 8% | 9% | 6% | 5% | 3% | 2% | 1% |
| Other Income | 56 | 5 | 2 | 1 | 1 | -4 | 5 | 3 | 3 | 6 | 12 | 17 | 17 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 7 | 7 | 7 | 5 | 4 |
| Profit before tax | 98 | 40 | 62 | 66 | 60 | 78 | 78 | 89 | 59 | 58 | 38 | 26 | 14 |
| Tax % | 18% | 39% | 38% | 41% | 34% | 38% | 36% | 30% | 34% | 40% | 48% | 56% | |
| Net Profit | 81 | 24 | 38 | 39 | 39 | 48 | 50 | 62 | 39 | 35 | 20 | 12 | 4 |
| EPS in Rs | 27.49 | 8.32 | 13.02 | 13.13 | 13.20 | 15.74 | 16.27 | 20.19 | 12.69 | 11.26 | 6.48 | 3.82 | 1.44 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | 5% | 2% | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -70.37% | 58.33% | 2.63% | 0.00% | 23.08% | 4.17% | 24.00% | -37.10% | -10.26% | -42.86% | -40.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 128.70% | -55.70% | -2.63% | 23.08% | -18.91% | 19.83% | -61.10% | 26.84% | -32.60% | 2.86% |
Trigyn Technologies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | -5% |
| TTM: | -27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -23% |
| 3 Years: | -30% |
| TTM: | -99% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | -10% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 5% |
| 3 Years: | 3% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 4, 2025, 2:08 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 29 | 29 | 30 | 30 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 193 | 218 | 260 | 297 | 341 | 403 | 473 | 527 | 577 | 650 | 670 | 710 | 731 |
| Borrowings | 0 | 0 | 0 | 0 | 1 | 8 | 6 | 10 | 7 | 7 | 5 | 13 | 7 |
| Other Liabilities | 49 | 51 | 57 | 58 | 75 | 100 | 108 | 115 | 140 | 168 | 168 | 150 | 148 |
| Total Liabilities | 271 | 299 | 347 | 385 | 446 | 541 | 618 | 683 | 755 | 856 | 874 | 903 | 916 |
| Fixed Assets | 92 | 91 | 88 | 89 | 90 | 90 | 100 | 99 | 108 | 107 | 103 | 97 | 96 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 0 | 0 | 0 |
| Investments | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 5 | 21 | 83 | 17 | 38 | 33 |
| Other Assets | 179 | 207 | 258 | 295 | 355 | 447 | 513 | 577 | 624 | 665 | 755 | 769 | 788 |
| Total Assets | 271 | 299 | 347 | 385 | 446 | 541 | 618 | 683 | 755 | 856 | 874 | 903 | 916 |
Below is a detailed analysis of the balance sheet data for Trigyn Technologies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 31.00 Cr..
- For Reserves, as of Sep 2025, the value is 731.00 Cr.. The value appears strong and on an upward trend. It has increased from 710.00 Cr. (Mar 2025) to 731.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 6.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 148.00 Cr.. The value appears to be improving (decreasing). It has decreased from 150.00 Cr. (Mar 2025) to 148.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 916.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 903.00 Cr. (Mar 2025) to 916.00 Cr., marking an increase of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 96.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2025) to 96.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 38.00 Cr. (Mar 2025) to 33.00 Cr., marking a decrease of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 788.00 Cr.. The value appears strong and on an upward trend. It has increased from 769.00 Cr. (Mar 2025) to 788.00 Cr., marking an increase of 19.00 Cr..
- For Total Assets, as of Sep 2025, the value is 916.00 Cr.. The value appears strong and on an upward trend. It has increased from 903.00 Cr. (Mar 2025) to 916.00 Cr., marking an increase of 13.00 Cr..
Notably, the Reserves (731.00 Cr.) exceed the Borrowings (7.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 44.00 | 36.00 | 62.00 | 67.00 | 60.00 | 77.00 | 71.00 | 82.00 | 58.00 | 54.00 | 30.00 | 5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 105 | 114 | 83 | 68 | 74 | 79 | 104 | 89 | 99 | 87 | 71 | 99 |
| Inventory Days | 9 | |||||||||||
| Days Payable | 407 | |||||||||||
| Cash Conversion Cycle | 105 | 114 | 83 | 68 | 74 | -319 | 104 | 89 | 99 | 87 | 71 | 99 |
| Working Capital Days | 75 | 82 | 57 | 42 | 50 | 62 | 71 | 56 | 57 | 72 | 53 | 64 |
| ROCE % | 29% | 17% | 24% | 22% | 17% | 21% | 17% | 17% | 10% | 9% | 6% | 4% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| Diluted EPS (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.11 |
| Cash EPS (Rs.) | 5.45 | 8.72 | 13.47 | 14.87 | 21.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 240.71 | 227.77 | 221.21 | 197.37 | 181.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 240.71 | 227.77 | 221.21 | 197.37 | 181.30 |
| Revenue From Operations / Share (Rs.) | 291.71 | 415.67 | 413.41 | 338.01 | 320.09 |
| PBDIT / Share (Rs.) | 11.51 | 15.18 | 21.85 | 22.18 | 30.80 |
| PBIT / Share (Rs.) | 9.88 | 12.95 | 19.64 | 20.01 | 29.79 |
| PBT / Share (Rs.) | 8.60 | 12.41 | 18.92 | 19.11 | 28.91 |
| Net Profit / Share (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| NP After MI And SOA / Share (Rs.) | 3.82 | 6.48 | 11.26 | 12.69 | 20.20 |
| PBDIT Margin (%) | 3.94 | 3.65 | 5.28 | 6.56 | 9.62 |
| PBIT Margin (%) | 3.38 | 3.11 | 4.75 | 5.91 | 9.30 |
| PBT Margin (%) | 2.94 | 2.98 | 4.57 | 5.65 | 9.03 |
| Net Profit Margin (%) | 1.31 | 1.56 | 2.72 | 3.75 | 6.30 |
| NP After MI And SOA Margin (%) | 1.31 | 1.56 | 2.72 | 3.75 | 6.30 |
| Return on Networth / Equity (%) | 1.58 | 2.84 | 5.09 | 6.43 | 11.13 |
| Return on Capital Employeed (%) | 4.03 | 5.58 | 8.73 | 10.01 | 16.14 |
| Return On Assets (%) | 1.30 | 2.28 | 4.05 | 5.17 | 9.10 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 1.01 | 1.48 | 1.58 | 0.20 | 0.20 |
| Current Ratio (X) | 4.82 | 4.26 | 3.36 | 3.69 | 4.02 |
| Quick Ratio (X) | 4.76 | 4.21 | 3.30 | 3.67 | 3.99 |
| Inventory Turnover Ratio (X) | 109.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 12.76 | 28.21 | 30.01 | 24.69 | 34.91 |
| Interest Coverage Ratio (Post Tax) (X) | 5.66 | 13.05 | 16.47 | 15.12 | 23.89 |
| Enterprise Value (Cr.) | -195.88 | -48.38 | 147.35 | 204.15 | 3.24 |
| EV / Net Operating Revenue (X) | -0.21 | -0.03 | 0.11 | 0.19 | 0.00 |
| EV / EBITDA (X) | -5.53 | -1.03 | 2.19 | 2.99 | 0.03 |
| MarketCap / Net Operating Revenue (X) | 0.23 | 0.22 | 0.22 | 0.39 | 0.19 |
| Price / BV (X) | 0.28 | 0.41 | 0.41 | 0.68 | 0.34 |
| Price / Net Operating Revenue (X) | 0.23 | 0.22 | 0.22 | 0.39 | 0.19 |
| EarningsYield | 0.05 | 0.06 | 0.12 | 0.09 | 0.32 |
After reviewing the key financial ratios for Trigyn Technologies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 5. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.45. This value is within the healthy range. It has decreased from 8.72 (Mar 24) to 5.45, marking a decrease of 3.27.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 240.71. It has increased from 227.77 (Mar 24) to 240.71, marking an increase of 12.94.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 291.71. It has decreased from 415.67 (Mar 24) to 291.71, marking a decrease of 123.96.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.51. This value is within the healthy range. It has decreased from 15.18 (Mar 24) to 11.51, marking a decrease of 3.67.
- For PBIT / Share (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has decreased from 12.95 (Mar 24) to 9.88, marking a decrease of 3.07.
- For PBT / Share (Rs.), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 12.41 (Mar 24) to 8.60, marking a decrease of 3.81.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.82. This value is within the healthy range. It has decreased from 6.48 (Mar 24) to 3.82, marking a decrease of 2.66.
- For PBDIT Margin (%), as of Mar 25, the value is 3.94. This value is below the healthy minimum of 10. It has increased from 3.65 (Mar 24) to 3.94, marking an increase of 0.29.
- For PBIT Margin (%), as of Mar 25, the value is 3.38. This value is below the healthy minimum of 10. It has increased from 3.11 (Mar 24) to 3.38, marking an increase of 0.27.
- For PBT Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 10. It has decreased from 2.98 (Mar 24) to 2.94, marking a decrease of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 5. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.31. This value is below the healthy minimum of 8. It has decreased from 1.56 (Mar 24) to 1.31, marking a decrease of 0.25.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 15. It has decreased from 2.84 (Mar 24) to 1.58, marking a decrease of 1.26.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.03. This value is below the healthy minimum of 10. It has decreased from 5.58 (Mar 24) to 4.03, marking a decrease of 1.55.
- For Return On Assets (%), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 5. It has decreased from 2.28 (Mar 24) to 1.30, marking a decrease of 0.98.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.01. It has decreased from 1.48 (Mar 24) to 1.01, marking a decrease of 0.47.
- For Current Ratio (X), as of Mar 25, the value is 4.82. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 24) to 4.82, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 25, the value is 4.76. This value exceeds the healthy maximum of 2. It has increased from 4.21 (Mar 24) to 4.76, marking an increase of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 109.49. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 109.49, marking an increase of 109.49.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 12.76. This value is within the healthy range. It has decreased from 28.21 (Mar 24) to 12.76, marking a decrease of 15.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.66. This value is within the healthy range. It has decreased from 13.05 (Mar 24) to 5.66, marking a decrease of 7.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is -195.88. It has decreased from -48.38 (Mar 24) to -195.88, marking a decrease of 147.50.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 1. It has decreased from -0.03 (Mar 24) to -0.21, marking a decrease of 0.18.
- For EV / EBITDA (X), as of Mar 25, the value is -5.53. This value is below the healthy minimum of 5. It has decreased from -1.03 (Mar 24) to -5.53, marking a decrease of 4.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
- For Price / BV (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.41 (Mar 24) to 0.28, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.23, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Trigyn Technologies Ltd:
- Net Profit Margin: 1.31%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.03% (Industry Average ROCE: 14.88%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.58% (Industry Average ROE: 20.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.66
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.4 (Industry average Stock P/E: 81.01)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.31%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | Unit 27, SDF 1, Mumbai Maharashtra 400096 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Satyam Cherukuri | Chairman & Non-Exe.Director |
| Ms. P Bhavana Rao | Executive Director |
| Mr. R Ganapathi | Non Executive Director |
| Dr. P Raja Mohan Rao | Non Executive Director |
| Ms. Lakshmi Potluri | Independent Director |
| Mr. Ishwar Halalli | Independent Director |
| Mr. Syed Ahmed Sultan | Independent Director |
| Mr. Vijay Mallya | Independent Director |
FAQ
What is the intrinsic value of Trigyn Technologies Ltd?
Trigyn Technologies Ltd's intrinsic value (as of 21 January 2026) is ₹81.66 which is 37.71% higher the current market price of ₹59.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹184 Cr. market cap, FY2025-2026 high/low of ₹116/58.6, reserves of ₹731 Cr, and liabilities of ₹916 Cr.
What is the Market Cap of Trigyn Technologies Ltd?
The Market Cap of Trigyn Technologies Ltd is 184 Cr..
What is the current Stock Price of Trigyn Technologies Ltd as on 21 January 2026?
The current stock price of Trigyn Technologies Ltd as on 21 January 2026 is ₹59.3.
What is the High / Low of Trigyn Technologies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Trigyn Technologies Ltd stocks is ₹116/58.6.
What is the Stock P/E of Trigyn Technologies Ltd?
The Stock P/E of Trigyn Technologies Ltd is 36.4.
What is the Book Value of Trigyn Technologies Ltd?
The Book Value of Trigyn Technologies Ltd is 247.
What is the Dividend Yield of Trigyn Technologies Ltd?
The Dividend Yield of Trigyn Technologies Ltd is 0.00 %.
What is the ROCE of Trigyn Technologies Ltd?
The ROCE of Trigyn Technologies Ltd is 4.17 %.
What is the ROE of Trigyn Technologies Ltd?
The ROE of Trigyn Technologies Ltd is 1.72 %.
What is the Face Value of Trigyn Technologies Ltd?
The Face Value of Trigyn Technologies Ltd is 10.0.